Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de extensão para pacientes previamente inscritos em estudos com Pelabresibe

6 de novembro de 2026 atualizado por: Novartis Pharmaceuticals

Um estudo de extensão multicêntrico aberto para pacientes previamente inscritos em estudos com Pelabresibe

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

The study will collect and monitor ongoing efficacy information with regard to disease and survival status, as well as safety information with regard to AEs, including SAEs and AEs of special interest (AESI).

Patients are eligible to continue pelabresib treatment as long as the regimen is tolerated, and the patient does not meet any of the discontinuation criteria.

Patients who have previously received pelabresib alone or pelabresib in combination with ruxolitinib or ruxolitinib alone will continue to receive the same regimen as administered in the parent study.

There will be an eligibility check period of up to 28 days for this extension study. Patients who fulfill the inclusion and exclusion criteria are eligible for the study. After the patient willingly provides consent, eligibility will be assessed by the investigator and treatment with pelabresib can be started at the same dose and dosing schedule that was applied in the parent study in the last cycle prior to EOT unless there is need for dose adjustment due to toxicity.

A patient is considered to have completed the study after completion of all visits as defined in the Schedule of Assessments (SoA) as per protocol, including the Safety Follow-up visit and Survival Follow-up.

The Safety Follow-up period is the interval between the EOT visit and the scheduled Safety Follow-up visit, which should occur 30 days (±3 days) after the last dose of pelabresib. For patients who switch from investigational pelabresib to commercial pelabresib treatment, the Safety Follow-up period is the time from the last dose of investigational pelabresib until the first dose of commercial pelabresib. The treatment start date with commercial pelabresib will be considered the date of "early Safety Follow-up termination." All patients will be followed for AEs and SAEs for 30 days (±3 days) following the last dose of pelabresib on the extension study or until the initiation of a new anticancer therapy, whichever occurs first.

Reasonable efforts should be made to have the patient return for the Safety Follow-up visit and review any AEs that may occur during this period. If the patient cannot return to the site for the Safety Follow-up visit, then the patient should be contacted by telephone for assessment of AEs.

The end of study will occur when all parent studies have been closed with no further patients expected to be enrolled into the extension study, and all patients are either discontinued or study treatment becomes commercially available and reimbursed, or an alternate access program becomes available, whichever comes first. Prior to study completion, all patients should.have completed the Safety Follow-up visit or have been designated as lost to follow-up, died, or have withdrawn consent, whichever comes first. The sponsor reserves the right to close a study site or terminate the study at any time for any reason at the sole discretion of the sponsor.

Tipo de estudo

Intervencional

Inscrição (Estimado)

50

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

      • Antwerp, Bélgica, 2030
        • Recrutamento
        • Novartis Investigative Site
      • Bruges, Bélgica, 8000
        • Recrutamento
        • Novartis Investigative Site
    • California
      • Los Angeles, California, Estados Unidos, 90095
        • Recrutamento
        • University of California LA
        • Investigador principal:
          • Gary Schiller
        • Contato:
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32224
        • Recrutamento
        • Mayo Clinic Jacksonville
        • Investigador principal:
          • Candido Rivera
        • Contato:
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Recrutamento
        • Northwestern University
        • Investigador principal:
          • Brady L Stein
        • Contato:
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Recrutamento
        • Uni Of Michigan Health System
        • Investigador principal:
          • Moshe Talpaz
        • Contato:
    • New York
      • New York, New York, Estados Unidos, 10021
        • Recrutamento
        • New York Presbyterian Hospital
        • Investigador principal:
          • Joseph Scandura
        • Contato:
      • New York, New York, Estados Unidos, 10029-6574
        • Recrutamento
        • Mt Sinai Medical Center
        • Investigador principal:
          • Marina Kremyanskaya
        • Contato:
      • Amsterdam, Holanda, 1081
        • Recrutamento
        • Novartis Investigative Site
      • Novara, Itália, 28100
        • Recrutamento
        • Novartis Investigative Site
    • FI
      • Florence, FI, Itália, 50134
        • Recrutamento
        • Novartis Investigative Site
    • VA
      • Varese, VA, Itália, 21100
        • Recrutamento
        • Novartis Investigative Site
      • Cardiff, Reino Unido, CF14 4XW
        • Recrutamento
        • Novartis Investigative Site
      • Glasgow, Reino Unido, G12 0YN
        • Recrutamento
        • Novartis Investigative Site
      • London, Reino Unido, SE1 7EH
        • Recrutamento
        • Novartis Investigative Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Able to provide signed informed consent, agreeing to all protocol and ICF requirements.

  • At least 18 years old and legally able to consent in the study's jurisdiction.

  • Previously enrolled and currently receiving pelabresib in combination with ruxolitinib or ruxolitinib alone in a parent study.

  • Demonstrating clinical benefit from pelabresib and/or ruxolitinib, as judged by the investigator.

  • Willing and able to follow all study visits, treatments, and procedures.

  • Agree to avoid pregnancy or fathering children:

    • Men: Must use highly effective contraception (≥99% effective) and avoid sperm donation from eligibility check through 94 days post-treatment.
    • Women of childbearing potential (WOCBP): Must test negative for pregnancy at eligibility, use highly effective contraception through 184 days post-treatment, undergo regular pregnancy testing, and avoid breastfeeding and oocyte donation during this period.
    • Women not of childbearing potential (surgically sterile or postmenopausal ≥12 months without other cause) are eligible.

Note: Women with amenorrhea due to chemo/radiotherapy are considered WOCBP and must use contraception.

Additional Inclusion Criteria control (placebo + ruxolitinib) group requiring pelabresib combination treatment:

  • On a stable dose of ruxolitinib for ≥8 weeks

  • Has adequate bone marrow and organ function as defined by the following local laboratory values:

    • ANC ≥ 1 × 10^9/L in the absence of growth factors for the previous 4 weeks
    • Platelet count ≥ 75 × 10^9/L in the absence of growth factors or platelet transfusions during previous 4 weeks
    • Peripheral blood blast count < 5%
    • AST and/or ALT ≤ 2.5 × ULN of the local reference interval (≤ 5 × if the elevation can be ascribed to hepatic MF involvement, e.g., presence of hepatomegaly)
    • Serum direct bilirubin < 2.0 × ULN of the local reference interval
    • Calculated or measured CrCl of ≥ 45 mL/min
  • Does not have any other concurrent medical condition that in the opinion of the investigator could compromise participation in the study

Exclusion Criteria:

  • Legally institutionalized or under judicial protection.
  • Enrolled in another interventional clinical trial (excluding the parent study).
  • History of hypersensitivity to pelabresib, its excipients, or similar drugs.
  • Significant gastrointestinal issues (e.g., active IBD, unresolved nausea/vomiting/diarrhea > Grade 1) that may affect drug absorption.
  • Any medical condition deemed unsuitable by the investigator.
  • Uncontrolled illness or condition that may compromise safety or protocol compliance.
  • Received systemic anticancer or investigational treatment (excluding parent study drug or hormonal therapy) within 2 weeks or 5 half-lives before first dose. (Hydroxyurea/anagrelide allowed up to 24 hours prior.)
  • Received hematopoietic growth factors or androgenic steroids within 4 weeks before first dose.
  • Used strong CYP3A4 inhibitors/inducers (e.g., St. John's wort) within 2 weeks before first dose. Use during treatment is prohibited.
  • Received immunosuppressive agents with systemic activity (>10 mg QD prednisone or equivalent) less than 4 weeks before the first dose of study drug in the extension study. Participants who received topical, nasal, intra-articular, inhaled, and other forms of corticosteroids without systemic activity are eligible
  • Received a live vaccination within 30 days prior to the first dose of study drug in the extension study, except for COVID-19 vaccination
  • Female participants who are pregnant, breastfeeding, or not using required contraception.
  • Male participants who do not agree to use contraception or refrain from sperm donation as specified.
  • Unwilling or unable to comply with the study protocol.

Additional Exclusion Criterion for participants receiving ruxolitinib only treatment

• Local access to commercially available and reimbursed ruxolitinib.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Pelabresib and/or ruxolitinib

Participants who have previously received pelabresib alone or pelabresib in combination with ruxolitinib or ruxolitinib alone will continue to receive the same regimen as administered in the parent study.

Additionally, the MANIFEST-2 (NCT04603495) control group (i.e., treated with placebo + ruxolitinib) patients, will be offered pelabresib combination treatment at the time of enrollment if the investigator sees any potential benefit of adding pelabresib to ruxolitinib.

Small molecule inhibitor of bromodomain and extraterminal (BET) protein

Outros nomes:
  • CPI-0610

Small molecule selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2.

Outros nomes:
  • Jakavi™/Jakafi™

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Treatment-emergent adverse events (TEAEs) and serious TEAEs
Prazo: 5 years

To evaluate long-term safety in patients who are receiving pelabresib

5 years
Survival Follow-up
Prazo: 5 years

Survival Follow-up consists of Survival and Leukemia-Free Survival Follow-up. All participants in the extension study will be followed up for Survival, while participants with hematological malignancies will be followed up for Survival and Leukemia-Free Survival.

5 years
Duration of Response (DoR)
Prazo: 5 years

DOR defined as the time from the date of first response to the date of confirmed disease progression

5 years
Progression-free survival (PFS)
Prazo: 5 years

PFS defined as the time from first dose to confirmed disease progression or death, whichever occurs first.

5 years
Leukemia-free survival (LFS)
Prazo: 5 years

LFS defined as the time from first dose to the date of leukemic transformation or death, whichever occurs first.

5 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

13 de agosto de 2024

Conclusão Primária (Estimado)

31 de dezembro de 2029

Conclusão do estudo (Estimado)

31 de dezembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

2 de maio de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de maio de 2024

Primeira postagem (Real)

6 de maio de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • CDAK539A12001B
  • CNST0610C210 (Outro identificador: Constellation Pharmaceuticals)
  • 2023-508950-24-00 (Identificador de registro: EU CT Number)
  • 2023 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .